N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide | 1318780-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide
• 英文别名: N-[4-[2-[(4-sulfamoylphenyl)methylamino]-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl]phenyl]cyclopropanecarboxamide
• CAS: 1318780-06-1
• 化学式: C₂₆H₂₄F₃N₇O₃S
• 分子量: 571.583
• InChiKey: DOCVYUGZJCOCGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide 、 三氟乙酸 以 水 、 乙腈 为溶剂， 以75 mg的产率得到N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide bis(trifluoroacetic acid) salt
  参考文献：
  名称：

  Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors

  摘要：

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).

  DOI：

  10.1021/ml200163b
• 作为产物：
  描述：

  2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 碳酸氢钠 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide
  参考文献：
  名称：

  Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors

  摘要：

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).

  DOI：

  10.1021/ml200163b

文献信息

• Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors
  作者：Scott E. Lazerwith、Gina Bahador、Eda Canales、Guofeng Cheng、Lee Chong、Michael O. Clarke、Edward Doerffler、Eugene J. Eisenberg、Jaclyn Hayes、Bing Lu、Qi Liu、Mike Matles、Michael Mertzman、Michael L. Mitchell、Philip Morganelli、Bernard P. Murray、Margaret Robinson、Robert G. Strickley、Megan Tessler、Neeraj Tirunagari、Jianhong Wang、Yujin Wang、Jennifer R. Zhang、Xubin Zheng、Weidong Zhong、William J. Watkins

  DOI：10.1021/ml200163b

  日期：2011.10.13

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).